Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

6533b858fe1ef96bd12b629c

RESEARCH PRODUCT

Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

A Saracino N Gianotti M Marangi Dc Cibelli A Galli G Punzi L Monno A Lazzarin G Angarano M Dini R Del Gobbo M Montroni L Butini G Scalise F Ancarani S Di Cesare A Giacometti A Biglino M Degioanni M Paoloni R Mariani G Calella G Pastore N Ladisa G Mennea Fm Gritti G Fasullo F Chiodo M Borderi Giampiero Carosi Francesco Castelli Carlo Torti C Uccelli G Rizzardini R Visoná A Salvo A Averna R Russo Bm Celesia S Cosentino E Rinaldi L Pusterla G Carnevale P Mondello C Petrini F Ghinelli L Sighinolfi F Mazzotta S Lo Caputo P Pierotti F Leoncini Gk Sterrantino P Corsi G Angarano A Saracino Ag Pompei Di Toro Mt Ag Pompei F Purificato F Indiveri M Setti G Murdaca A Iannessi A Cellini A Mariani A Scasso M De Gennaro A Chiodera P Castelli K Maltempo G Mongolo A Lazzarin N Gianotti L Caggese I Schlacht A Cargnel C Atzori V Micheli M Moroni T Bini I Marcatto E Chiesa G Vigevani B Argenteri A Capetti R Esposito G Guaraldi B Seghetto A Chirianni M Gargiulo N Abrescia M D'abbraccio T Busto C Marchitelli M Santirocchi V Abbadessa S Mancuso F Meneghetti M Pranzetti C Ferrari P Pizzaferri G Stagni F Di Candilo E Petrelli M Balducci F Menichetti M Polidori C Tascini A Di Carlo G Palamara A Antinori G Liuzzi F Aiuti I Mezzaroma E Pinter B Barbone V Vullo P Massetti S Dell'isola Ms Mura M Mannazzu R Delias D Di Giammartino P Tarquini F Marranconi R Ferretto P Caramello Gc Orofino T Cimino C Bramato G Di Perri A Sinicco D Zeme S Bonora L Trentini Ml Soranzo A Macor B Salassa F Branz P Delle Foglie A Vaglia Mc Rossi L Ciccone L Panzolli P Grossi M Giola E Raise E Narne A Poggio F Demin V Mondino G Serpelloni M Malena O. Bosco

subject

Anti-HIV Agents DNA Mutational Analysis Molecular Sequence Data Proviral DNA HIV Infections HAART failure medicine.disease_cause DNA Mutational Analysi chemistry.chemical_compound HIV Protease Proviruses Antiretroviral Therapy Highly Active Virology Drug Resistance Viral DNA Mutational Analysis medicine Humans Multicenter Studies as Topic HIV Infection Treatment Failure Genotyping Randomized Controlled Trials as Topic COLD-PCR Mutation Plasma RNA biology Proviruse Sequence Analysis RNA Anti-HIV Agent RNA Sequence Analysis DNA biology.organism_classification Virology HIV Reverse Transcriptase Reverse transcriptase Antiretroviral genotypic resistance Infectious Diseases chemistry DNA Viral Mutation Lentivirus Immunology HIV-1 RNA Viral DNA antiretroviral genotypic resistance; haart failure; hiv-1; plasma rna; proviral dna Human

description

The extent to which HIV-1 proviral DNA mutations cause clinically relevant antiretroviral resistance is still controversial. Paired plasma HIV-1 RNA and whole blood DNA were compared in patients failing HAART to investigate if the additional knowledge of archived mutations could improve the selection of potentially active drugs. Seventy-three HIV-1-infected patients with first/second HAART failure were studied before starting a new regimen based on RNA genotyping. Follow-up data after a 12-week therapy were available. DNA genotyping was retrospectively performed on stored whole blood samples and mutational profiles were compared to those from RNA. The mean number of IAS pol mutations was significantly higher in RNA (4.45 ± 2.76) than in DNA (2.88 ± 2.47) (P < 0.001). DNA genotyping provided a 6% increase in detection of resistance-associated mutations. Among 64/73 patients showing discordant DNA/RNA profiles, 54 (84%) also differed for predicted active drugs. 16/73 (22%) patients had ≥1 mutation revealed by DNA genotyping alone, probably affecting therapy success in 2/16. However, neither RNA/DNA discordance nor detection of isolated DNA mutations were statistically associated with outcome. In conclusion, plasma RNA remains the elective choice for HIV genotyping in patients with therapy failure, even if the detection of proviral resistance-associated mutations, not simultaneously found in RNA, is a frequent event. Therefore, in some cases DNA plus RNA genotyping might assist in choosing more accurately subsequent antiretroviral regimens. © 2008 Wiley-Liss, Inc.

year	journal	country	edition	language
2008-01-01	Journal of Medical Virology

https://doi.org/10.1002/jmv.21261